236 related articles for article (PubMed ID: 36636997)
21. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
[TBL] [Abstract][Full Text] [Related]
22. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
[TBL] [Abstract][Full Text] [Related]
23. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
24. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
26. Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
Wang L; Howlett S; Essapen S
Semin Oncol; 2022 Apr; 49(2):170-177. PubMed ID: 35027218
[TBL] [Abstract][Full Text] [Related]
27.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
[TBL] [Abstract][Full Text] [Related]
28. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
[TBL] [Abstract][Full Text] [Related]
29. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
[TBL] [Abstract][Full Text] [Related]
30. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
Nguyen DG; Morris SA; Chen A; Moore DC; Hanson SL; Larck C; Musselwhite LW; Turner JD; Salem ME; Kwange SO; Hamilton A; Steuerwald N; Patel JN
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754463
[TBL] [Abstract][Full Text] [Related]
31. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
[TBL] [Abstract][Full Text] [Related]
32. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
[TBL] [Abstract][Full Text] [Related]
33. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
34. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
[TBL] [Abstract][Full Text] [Related]
35. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare
van Kuilenburg ABP; Pleunis-van Empel MCH; Brouwer RB; Sijben AEJ; Knapen DG; Oude Munnink TH; van Zanden JJ; Janssens-Puister J; Dobritzsch D; Meinsma R; Meijer-Jansen J; van Dooren SJM; Vijzelaar R; Pop A; Salomons GS; Maring JG; Niezen-Koning KE
JCO Precis Oncol; 2024 May; 8():e2300599. PubMed ID: 38709992
[TBL] [Abstract][Full Text] [Related]
36. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
De Luca O; Salerno G; De Bernardini D; Torre MS; Simmaco M; Lionetto L; Gentile G; Borro M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430399
[TBL] [Abstract][Full Text] [Related]
37. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Madi A; Fisher D; Maughan TS; Colley JP; Meade AM; Maynard J; Humphreys V; Wasan H; Adams RA; Idziaszczyk S; Harris R; Kaplan RS; Cheadle JP
Eur J Cancer; 2018 Oct; 102():31-39. PubMed ID: 30114658
[TBL] [Abstract][Full Text] [Related]
39.
Ragia G; Biziota E; Koukaki T; Amarantidis K; Manolopoulos VG
Pharmacogenomics; 2024 Jan; 25(2):59-67. PubMed ID: 38353109
[TBL] [Abstract][Full Text] [Related]
40. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
